Market Overview:
The global vaginitis therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of vaginitis, rising awareness about available treatments, and growing demand for novel therapies. Based on type, the global vaginitis therapeutics market is segmented into anti-fungal, anti-bacterial, hormone therapy, and other therapies. The anti-fungal therapy segment is expected to account for the largest share of the global vaginitis therapeutics market in 2018. This segment is projected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030 due to increasing incidence of fungal infections worldwide. Based on application, the global vaginitis therapeutics market is divided into atrophic vaginitis, bacterial vaginosis (BV), trichomoniasis vaginalis (TV), candidiasis (thrush), and other applications.
Product Definition:
Vaginitis is a condition that results in inflammation of the vagina. Symptoms may include discharge, itching, and burning. Vaginitis can be caused by bacteria, viruses, or other organisms such as parasites. It can also be caused by chemicals irritants or allergic reactions. Treatment depends on the cause of the vaginitis.
Anti-fungal:
Anti-fungal is a drug or medication that prevents fungal infections. Fungi are organisms that reproduce by budding off spores, which may cause infection in humans and animals. The most common types of fungi are molds, yeasts, and mushrooms; the most common mold is called asmallothecium fungus or white powdery mildew.
Anti-bacterial:
Antibacterial is a drug that prevents the growth of bacteria. Some antibacterial drugs include cephalosporin, penicillin, macrolide antibiotics and tetracycline. Antibiotics are used to treat bacterial vaginosis (BV), urinary tract infections (UTI) and skin infections including cellulitis, furunculosis, necrotizing infection or boil.
Application Insights:
Based on the application, the global market is segmented into atrophic vaginitis, bacterial vaginosis (BV), trichomoniasis vaginalis (T. vaginalis), Candida albicans (C. albicans), and others. Atrophic vaginitis held the largest share in 2017 due to increasing prevalence of aging and post-menopausal women are more susceptible to this condition than men. Bacterial vaginosis is expected to be the fastest growing segment over forecast period owing to rising awareness about maintaining good hygiene and appropriate management of sex life among women after marriage as well as before marriage period which may result in increased usage of these products by them during this time frame.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the high prevalence of BV, CAUTIs, and yeast infections among women in this region. According to a study published by National Institute of Health (NIH), around 25% - 40% of all women are estimated to be affected with at least one form of vaginal infection during their lifetime. Furthermore, increasing awareness about these infections and availability of effective treatment methods are some other factors contributing toward regional growth.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income levels and growing population especially in India & China & Japan which will result into an increase in incidence rates for various vaginal diseases including bacterial vaginosis (BV), trichomoniasis, candidiasis etc., over this period.
Growth Factors:
- Increasing incidence of vaginitis
- Rising awareness about the available treatment options for vaginitis
- Growing demand for effective and safe over-the-counter (OTC) treatments for vaginitis
- Proliferation of online resources and support groups devoted to helping women with vaginitis 5. Emerging therapies and products that could offer better outcomes and fewer side effects than currently available treatments
Scope Of The Report
Report Attributes
Report Details
Report Title
Vaginitis Therapeutics Market Research Report
By Type
Anti-fungal, Anti-bacterial, Hormone, Other
By Application
Atrophic Vaginitis, Bacterial Vaginosis, Trichomonas Vaginalis, Candida Albicans, Other
By Companies
Bayer AG, Lupin Pharmaceuticals, Inc, Merck & Co, Mission Pharmacal Company, Novartis AG, Pfizer, Inc, Symbiomix Therapeutics, Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Vaginitis Therapeutics Market Report Segments:
The global Vaginitis Therapeutics market is segmented on the basis of:
Types
Anti-fungal, Anti-bacterial, Hormone, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Atrophic Vaginitis, Bacterial Vaginosis, Trichomonas Vaginalis, Candida Albicans, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer AG
- Lupin Pharmaceuticals, Inc
- Merck & Co
- Mission Pharmacal Company
- Novartis AG
- Pfizer, Inc
- Symbiomix Therapeutics, Inc
Highlights of The Vaginitis Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-fungal
- Anti-bacterial
- Hormone
- Other
- By Application:
- Atrophic Vaginitis
- Bacterial Vaginosis
- Trichomonas Vaginalis
- Candida Albicans
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Vaginitis Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Vaginitis Therapeutics is a clinical stage biotechnology company focused on the development of novel therapeutics for women's health. The Company's lead product candidate, V-971, is an investigational vaginal gel formulation that is designed to improve symptoms of vaginitis.
Some of the key players operating in the vaginitis therapeutics market are Bayer AG, Lupin Pharmaceuticals, Inc, Merck & Co, Mission Pharmacal Company, Novartis AG, Pfizer, Inc, Symbiomix Therapeutics, Inc.
The vaginitis therapeutics market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Vaginitis Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Vaginitis Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Vaginitis Therapeutics Market - Supply Chain
4.5. Global Vaginitis Therapeutics Market Forecast
4.5.1. Vaginitis Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Vaginitis Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Vaginitis Therapeutics Market Absolute $ Opportunity
5. Global Vaginitis Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Vaginitis Therapeutics Market Size and Volume Forecast by Type
5.3.1. Anti-fungal
5.3.2. Anti-bacterial
5.3.3. Hormone
5.3.4. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Vaginitis Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Vaginitis Therapeutics Market Size and Volume Forecast by Application
6.3.1. Atrophic Vaginitis
6.3.2. Bacterial Vaginosis
6.3.3. Trichomonas Vaginalis
6.3.4. Candida Albicans
6.3.5. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Vaginitis Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Vaginitis Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Vaginitis Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Vaginitis Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Vaginitis Therapeutics Demand Share Forecast, 2019-2029
9. North America Vaginitis Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Vaginitis Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Vaginitis Therapeutics Market Size and Volume Forecast by Application
9.4.1. Atrophic Vaginitis
9.4.2. Bacterial Vaginosis
9.4.3. Trichomonas Vaginalis
9.4.4. Candida Albicans
9.4.5. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Vaginitis Therapeutics Market Size and Volume Forecast by Type
9.7.1. Anti-fungal
9.7.2. Anti-bacterial
9.7.3. Hormone
9.7.4. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Vaginitis Therapeutics Demand Share Forecast, 2019-2029
10. Latin America Vaginitis Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Vaginitis Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Vaginitis Therapeutics Market Size and Volume Forecast by Application
10.4.1. Atrophic Vaginitis
10.4.2. Bacterial Vaginosis
10.4.3. Trichomonas Vaginalis
10.4.4. Candida Albicans
10.4.5. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Vaginitis Therapeutics Market Size and Volume Forecast by Type
10.7.1. Anti-fungal
10.7.2. Anti-bacterial
10.7.3. Hormone
10.7.4. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Vaginitis Therapeutics Demand Share Forecast, 2019-2029
11. Europe Vaginitis Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Vaginitis Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Vaginitis Therapeutics Market Size and Volume Forecast by Application
11.4.1. Atrophic Vaginitis
11.4.2. Bacterial Vaginosis
11.4.3. Trichomonas Vaginalis
11.4.4. Candida Albicans
11.4.5. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Vaginitis Therapeutics Market Size and Volume Forecast by Type
11.7.1. Anti-fungal
11.7.2. Anti-bacterial
11.7.3. Hormone
11.7.4. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Vaginitis Therapeutics Demand Share, 2019-2029
12. Asia Pacific Vaginitis Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Vaginitis Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Vaginitis Therapeutics Market Size and Volume Forecast by Application
12.4.1. Atrophic Vaginitis
12.4.2. Bacterial Vaginosis
12.4.3. Trichomonas Vaginalis
12.4.4. Candida Albicans
12.4.5. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Vaginitis Therapeutics Market Size and Volume Forecast by Type
12.7.1. Anti-fungal
12.7.2. Anti-bacterial
12.7.3. Hormone
12.7.4. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Vaginitis Therapeutics Demand Share, 2019-2029
13. Middle East & Africa Vaginitis Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Vaginitis Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Vaginitis Therapeutics Market Size and Volume Forecast by Application
13.4.1. Atrophic Vaginitis
13.4.2. Bacterial Vaginosis
13.4.3. Trichomonas Vaginalis
13.4.4. Candida Albicans
13.4.5. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Vaginitis Therapeutics Market Size and Volume Forecast by Type
13.7.1. Anti-fungal
13.7.2. Anti-bacterial
13.7.3. Hormone
13.7.4. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Vaginitis Therapeutics Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Vaginitis Therapeutics Market: Market Share Analysis
14.2. Vaginitis Therapeutics Distributors and Customers
14.3. Vaginitis Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bayer AG
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Lupin Pharmaceuticals, Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Merck & Co
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Mission Pharmacal Company
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novartis AG
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Pfizer, Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Symbiomix Therapeutics, Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
